SEIKAGAKU CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 737 JPY | 0.00% |
|
-0.41% | -3.15% |
ETFs positioned on Seikagaku Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 15 M€ | +7.34% | ||
| 0.01% | 18 M€ | +16.15% | - | |
| 0.01% | 144,586 M€ | +14.49% | ||
| 0.01% | 66,066 M€ | +14.68% | - | |
| 0.01% | 20,721 M€ | +13.52% | - |
SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
737
JPY
Average target price
800
JPY
Spread / Average Target
+8.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.15% | 255M | |
| +25.83% | 661B | |
| +26.54% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.72% | 231B | |
| +5.27% | 200B | |
| -8.75% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 4548 Stock
- Funds and ETFs Seikagaku Corporation
